Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Open Access
- 1 April 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (2) , 145-153
- https://doi.org/10.1215/s1152851703000498
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.2002
- Altered irinotecan metabolism in a patient receiving phenytoinAnti-Cancer Drugs, 2002
- Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenograftsCancer Chemotherapy and Pharmacology, 2000
- Irinotecan Therapy in Adults With Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 1999
- Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agentsCancer Chemotherapy and Pharmacology, 1998
- The basis for current treatment recommendations for malignant gliomasJournal of Neuro-Oncology, 1994
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignanciesBlood Reviews, 1992
- Therapy of adult malignant brain tumors: what have the clinical trials taught us?1986
- Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomasJournal of Neurosurgery, 1985